OncoSynergy improves outcomes for patients with unmet needs in oncology with Resistance Mechanism Inhibitors (RMIs). Founded by Anne-Marie Carbonell, Catherine Park, and Shawn Carbonell in 2011, OncoSynergy is backed by investors that include Connecticut Innovations, NLabs, and Korea Information & Communication Co. and is headquartered in Greenwich.